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HIF-1αThe pharmacological modulation of putative renoprotective factors hypoxia-inducible factor-1α (HIF-1α) and
HIF-1α-regulated vascular endothelial growth factor-A (VEGF-A) in the kidney has therapeutic interest. In
human renal proximal tubular HK2 cells, prostaglandin E2 (PGE2) up-regulates HIF-1α and VEGF-A through epi-
dermal growth factor receptor (EGFR)-dependent up-regulation of retinoic acid receptor-β (RARβ). Here we
studied the role of mitogen-activated protein kinases (MAPKs) ERK1/2 and p38 and their target kinase,
mitogen- and stress activated kinase-1 (MSK1), in the signaling cascade. Treatment of HK2 cellswith PGE2 result-
ed in increased phosphorylation of EGFR, the three studied kinases and the histone H3 (Ser10) at the RARβ gene
promoter (the latter has been proposed as a molecular signature of the activated RARβ gene promoter). Preven-
tion of the phosphorylation of EGFR, ERK1/2, p38 MAPK or MSK1 is by incubating, respectively, with AG1478,
PD98059, SB203580 or H89 allowed to elucidate the precise phosphorylation order in the signaling cascade trig-
gered by PGE2: ﬁrst, EGFR; then, ERK1/2 and p38MAPK and,ﬁnally,MSK1. Phosphorylation ofMSK1 led to that of
Ser10 in histone H3 and to activation of RARβ gene transcription (and the consequent increase in the expression
of HIF-1α and VEGF-A), which was suppressed by H89 or by transfecting cells with a vector encoding for a
dominant-negative mutant of MSK1. These results highlight the relevance of MSK1 in the up-regulation of
RARβ by PGE2. They alsomay contribute to new therapeutic approaches based upon the pharmacological control
of HIF-1α/VEGF-A in the proximal tubule through the modulation of the PGE2/EGFR/MAPK/MSK1/RARβ
pathway.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Hypoxia-inducible factor (HIF) is a heterodimer transcription factor
consisting of a constitutively expressed β subunit and two α subunits,
HIF-1α or HIF-2α [1]. Besides hypoxia, several physiological regulators
such as growth factors, hormones, stress factors and inﬂammatory me-
diators, increase HIF-1α expression [2]. HIF has important roles in the
kidney in terms of tumorigenesis, inﬂammation, progressive renal fail-
ure and protection in severalmodels of renal disease [3,4].We have pre-
viously found [5] in human proximal tubular HK-2 cells that HIF-1α is
up-regulated by all-trans retinoic acid (ATRA), which results in in-
creased production of vascular endothelial growth factor-A (VEGF-A, a
renoprotective factor) [6–11]. The mechanismwas critically dependent
on the up-regulation of retinoic acid receptor-β by ATRA [12,13].acid receptor-β; HIF-1α, factor
othelial growth factor-A; EGFR,
acid; RARE, retinoic acid recep-
d kinase-1
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ez-Martínez).ATRA is the physiological ligand of retinoic acid receptors (RARs).
RARs, which consist of three subtypes α, β and γ, act as ligand-
regulated transcription factors by dimerizing with retinoid X receptors
(RXR) and binding to retinoic acid response elements (RARE) located
in regulatory regions of target genes [14]. One of the target genes of
RARs is RARβ itself [15]. In its promoter region, it was identiﬁed a
RARE (β-RARE) which mediates ATRA-induced transcriptional RARβ
up-regulation in many different cell types [16]. Given its sensitivity to
ATRA, RARβ provides a mechanism for amplifying ATRA signaling. Our
studies in HK-2 cells and other cell lines have shown that prostaglandin
E2 (PGE2) plays a critical role in the up-regulation of RARβ by ATRA [17].
Accordingly, treatment with PGE2 reproduces the full sequence of
events triggered by ATRA: ﬁrst, activation of epidermal growth factor
receptor (EGFR) and then EGFR-dependent transcriptional up-
regulation of RARβ leading to increased expression of HIF-1α. As one
may expect, inhibition of PGE2 production by diclofenac prevents the
mentioned sequence of events in ATRA-treated cells.
Following EGFR activation, several downstream signaling cascades
can then be activated, including the Ras-mitogen-activated protein ki-
nase (MAPK) pathway, that depends on extracellular-signal regulated
kinase (ERK) and p38 MAPK activity [18–20]. ERK and p38 MAPK are
the activators of mitogen- and stress-activated protein kinase-1
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regulation since: i) activation of gene transcription by RARα (RARβ
being one of RARα target genes [22]) upon treatment with ATRA is de-
pendent on the phosphorylation of RARα at Ser369 and histone H3 at
Ser10 byMSK1 [23], ii) ATRA-induced RARβ gene transcription requires
speciﬁcally phosphorylation of histone H3 at Ser10 [24], and iii) the
EGFR ligand epidermal growth factor activates RARβ promoter by a
Ras-dependent mechanism [25], which may involve activation of
MSK1 by the MAPK pathway.
Taking into account this background, we studied the role of EGFR-
dependent activation of the MAPK/MSK1 pathway in HK-2 cells in
PGE2-induced transcriptional up-regulation of RARβ leading to in-
creased expression of HIF-1α and production of VEGF-A.
2. Methods
2.1. Materials and methods
2.1.1. Reagents
All trans-retinoic acid (ATRA), prostaglandin E2 (PGE2), AG1478, H89,
SB203580 and PD98059 were purchased from Sigma (St. Louis, MO). Ni-
trocellulose membrane was from Bio-Rad (Hercules, CA). Enhanced
chemiluminescence ECL detection system was from Amersham Biosci-
ences (Airlington, Heights, IL). Antibody against HIF-1α was purchased
from BD Biosciences (Palo Alto, CA), rabbit anti-phosphoEGFR, rabbit
anti-phospho38, rabbit anti ERK and rabbit phospho-MSK1 antibodies
were from Santa Cruz Biotechnology (Temecula, CA), CA). Rabbit anti-
RARβ was from Abcam (Cambridge, UK), rabbit anti H3 and anti-
phospho-Histone 3 (Ser10) were from Cell Signaling (Danvers, MA) and
an anti-β-actin antibody was from Sigma Chemical Co (St. Louis, MO).
2.1.2. Cell culture and treatments
Human proximal tubular epithelial cells (HK-2) were purchased
from American Type Culture Collection (Rockville, MD). HK-2 cells
were maintained in DMEM/F12 supplemented with 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin/amphoterycin B and 1% gluta-
mine (Invitrogen, Carlsbad, CA) and 1% Insulin–Transferrine–Selenium
(Sigma, St. Louis, MO).
Non-neoplastic, immortalized adult human prostatic epithelial cells
(RWPE-1) are androgen-responsive and showmanynormal cell charac-
teristics [26] and the cell line PC3 was obtained from the American
Type Culture Collection. RWPE-1 cells were maintained in complete
keratinocyte serum-free medium (K-SFM) containing 50 μg/ml bovine
pituitary extract and 5 ng/ml epidermal growth factor. PC3 cells were
grown and maintained in RPMI-1640 medium supplemented with
10% fetal bovine serum (FBS).
All culture media were also supplemented with 1% penicillin/
streptomycin/amphoterycin B (Life Technologies). The culture was per-
formed in a humidiﬁed 5%CO2 environment at 37 °C. In all experiments,
cells were plated at 70–90% conﬂuence and 24 h later theywere treated
with 10 μM ATRA or 1 μM PGE2 for different periods of time, 10 μM
AG1478, 1 μM H89 or 10 μM SB203580 and 20 μM PD98059 were
added 1 h before the treatment. Samples were immediately analyzed
except samples for the determination of the production of VEGF-A,
which were stored at−80 °C until analyzed.
2.1.3. Protein isolation and Western-blotting
HK-2 cells were stimulated for different time periods were washed
twice with ice-cold PBS and then harvested, scraped into ice-cold PBS,
and then pelleted by centrifugation at 500 ×g for 5 min at 4 °C. Cells
were kept on ice for 30 min and homogenized in a solution containing
50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate and protease inhibitors. Western blot analysis was per-
formed in cell lysates as previously described [5] using mouse anti-HIF-
1α (1:1000), rabbit anti-RARβ (1:500), rabbit anti-phospho-EGFR
(1:500), rabbit anti-phospho-p38 (1:1000), rabbit anti-phospho ERK(1:1000), rabbit phospho-MSK1 (1:2000), rabbit anti-H3 (1:10000),
and rabbit phospho-H3 (Ser10) (1:5000).
2.1.4. Isolation of histone proteins
For the isolation of histone proteins, HK-2 cells were seeded into
p100 plates (1.5 × 106 cells per well). After the deprivation, cells were
homogenized in 0.3 ml nuclear preparation buffer (10 mM Tris–HCl
(pH 7.6), 150 mM NaCl, 1.5 mM MgCl2, 0.65% NP-40, 1 mM PMSF and
protease inhibitor cocktail) as previously described [27]. Nuclei were re-
covered by centrifugation at 1.5 ×g for 15 min at 4 °C. Pellets were re-
suspended in 0.2 ml resuspended buffer: 10 mM Tris–HCl (pH 7.6), 3
mM MgCl2, 10 mM NaCl, 1 mM PMFS and inhibitor protease cocktail.
Nuclei were extracted with 0.4 N H2SO4 to isolate total proteins. The
samples were precipitatedwith trichloroacetic acid and then, incubated
on ice for 1 h, and centrifuged at 12,000 ×g, for 10 min. Pellets were
washed twice with ice cold acetone and then resuspended in 20 mM
Tris–HCl (pH 7.6).
2.1.5. Single-step real-time quantitative RT-PCR
HK-2 cells (0.5 × 106 cells) were stimulated with 10 μM ATRA, for
different periods of time. Total cell RNA was isolated with TriReagent
(Sigma) according to the instructions of the manufacturer. Real-time
quantitative RT-PCR analysis was performed using SYBR Green PCR
master mix, in one-step RT-PCR protocol according to the
manufacturer's protocol (Applied Biosystems). 45 ng RNA samples
were used. The thermal cycling parameters were 30 min at 48 °C for
RT and 10 min at 95 °C for activation polymerase enzyme, followed by
40 cycles of 95 °C for 15 s and 60 °C for 1 min. The primer sequences
for RARβ mRNA and the housekeeper gene β-actin are as indicated
(sequences 5′→3′): RARβ sense: GGTTTCACTGGCTTGACCAT, antisense
AAGGCCGTCTGAGAAAGTCA; HIF-1α sense: GAAAGCGCAAGTCCTCAA
AG, antisense: TGGGTAGGAGATGGAGATGC; VEGF165 sense: GACAAG
AAAATCCCTGTGGGCAAC, antisense: GCGAGTCTGTGTTTTTGC; β-actin
sense: GGTTTCACTGGCTTGACCAT; and antisense CATGTCCCAGTTGG
TGAC. All PCR reactions were performed in a PCR system ABI-Prism
7000 SDS (Applied Biosystems). Results of real-time PCR were repre-
sented as Ct values,where Ctwas deﬁned as the threshold cycle number
at which product is ﬁrst detected by ﬂuorescence. The amount of target
was normalized to an endogenous reference, the housekeeping gene for
β-actin. ΔCt was the difference in Ct values derived from the corre-
sponding gene in each sample assayed and β-actin gene. ΔΔCt repre-
sented the difference between paired samples. The n-fold differential
ratio was expressed as 2−ΔΔCt [28].
2.1.6. Chromatin immunoprecipitation assay (ChIP)
3 × 106 cells were grown in p150 plates, treated with 1 μM PGE2 for
different periods of time and then crosslinked with 1% formaldehyde at
room temperature for 15 min and the reaction stopped by 0.125 M gly-
cine for 5min. Cells werewashedwith ice-cold PBS and lysed in 1% SDS,
10 mM EDTA, 50 mM Tris–HCl (pH 8.1) and protease inhibitors. DNA
was sheared by sonication and cell lysates centrifuged for 10 min.
Supernatants were diluted 10-fold in 0.01% SDS. 1.1% Triton X-100,
1.2 mM EDTA, 16.7 mM Tris–HCl (pH 8.1), 167 mM NaCl and protease
inhibitors and immunocleared with 80 ml of protein A/G PLUS-
Agarose (Santa Cruz Biotechnology) for 1 h at 4 °C. Immune complexes
were formed overnight with the speciﬁc antibody anti-H3 (ser 10) and
collected with 50 ml of protein A/G PLUS-Agarose for 1 h. Beads were
washed for 1 min in buffer A (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris–HCl (pH 8.1), 150 mM NaCl), buffer B (0.1% SDS, 1% Triton
X-100, 2 mM EDTA; 20 mM Tris–HCl (pH 8.1), 500 mM NaCl), buffer C
(0.25 M LiCl, 1% NP-40, 1% deoxicolate, 1 mM EDTA, 10 mM Tris–HCl
(pH 8.1) and twice in buffer TE (10 mM Tris–HCl, 1 mM EDTA pH8).
Immunocomplexes were eluted off the beads for 15 min, with 1% SDS,
0.1 M NaHCO3) and crosslinks were reversed (4 h at 65 °C with 20 ml
of 5 M NaCl). DNAs were puriﬁed following phenol-chloroformed
method. Semi-quantitative PCR was performed as follows: 1 cycle at
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59 °C for 1 min, extension at 72 °C for 1 min using the following primer
sequences: fw 5′_GGGTAGGGTTCACCGAAAGT_3′; (rv) 5′_CATGGGG
GAATTCTGGTCCC_3′. DNA sequences were qualitatively evaluated
by agarose gel electrophoresis and SafeView nucleic acid stain (NBS
Biological) staining of PCR ampliﬁcation products.
2.1.7. Cell transfection
The plasmid pCMV5-Flag-D565/A-MSK1 (with an Asp-to-Ala muta-
tion at codon 565) was kindly provided by Dr. D. Alessi (The University
of Dundee, Scotland, UK). Cells, 2.5 × 105 per well, were plated in 6-well
plates 24 h before transfection. The cells were incubated for 12 h at
37 °C with 1 ml OptiMEM (Invitrogen, CA) containing complexes of
10 μl lipofectamine (Invitrogen, CA) and 1 μg MSK1 dominant negative
construct. Transfected cells were next incubated with complete growth
medium for 24 h and then treated as indicated in the Results section.
Transient transfection with reporter luciferase plasmid tk-β-RARE-
Luc (the plasmid, which contains a part of the RARE sequence from
the promoter of the human RARβ gene, was a generous gift from Prof.
Ronald Evans (The Salk institute, CA, USA) and was performed as fol-
lows: 2.5 × 106 cells per well were plated in 6-well plates 24 h before
transfection. Cells were incubated 12 h at 37 °C with 1 ml OptiMEM
(Invitrogen, CA) containing complexes of 5 μl lipofectamine (Invitrogen,
CA), 1 μg human tk-β-RARE-Luc and 1 μg renilla luciferase reporter as an
internal control. Transfected cells were next incubated with complete
growth medium for 24 h. Finally, ﬁreﬂy luciferase activity of the tk-β-
RARE-Luc reporter was measured with a Lumat LB9506 luminometer
(Berthold Technologies, Herts, UK) and normalized against renilla lucif-
erase activity by using the dual-luciferase reporter assay system
(Promega, Madison, WI).
2.1.8. Immunoﬂuorescence analysis
Cells were ﬁxed with 2% paraformaldehyde in PBS for 10 min at RT,
permeabilized with 0.1% Triton X-100, for 10 min, at RT and rinsed in
PBS. Cells were then incubated for 30 min with 4% BSA in PBS to block
nonspeciﬁc binding. Afterwards, cells were incubated overnight at
4 °C with anti-phospho MSK1 or anti-phospho H3 (Ser10) (1:50), and
then washed with PBS. Finally, cells were incubated with α-rabbit-
Alexa-Fluor® 488 (1:1000) for 1 h in the darkness. Slides were then
washed and mounted with ProLong Gold antifade reagent with DAPI
(Invitrogen). Detection was performed by confocal laser scanmicrosco-
py LEICA TCS-SL (Heidelberg, Germany).
2.1.9. Determination of VEGF secretion
HK-2 cells were placed in 24well plates (5 × 104 cells/well) for 24 h.
After an incubation period of 48 h with the treatment, the mediumwas
removed and kept at−80 °C for ELISA assays. VEGFwas analyzed using
human VEGF DuoSet (R&D Systems, Minneapolis, MN, USA) following
the manufacturer's instructions.
2.1.10. Statistical analysis
Each experiment was repeated at least three times. Results are
expressed as the mean ± S.E.M. Statistical analysis was performed by
nonparametric Bonferroni test. A P b 0.05 was considered statistically
signiﬁcant.
3. Results
The central aim of the present work was to determine the role of
the MAPK/MSK1 pathway in PGE2-induced increase in RARβ expres-
sion. We started targeting MSK1 by pre-treating HK-2 cells with MSK1
inhibitor H89 and/or transfecting them with a vector encoding for
a dominant-negative mutant of MSK1 (dn565 MSK1, a gift from
Dr. D. Alessi, The University of Dundee, Scotland, UK) before treatment
with PGE2. In these conditions, the increase in the expression of RARβ
induced by PGE2, as well as the consequent transcriptional increase inHIF-1α expression – which leads to enhanced production of VEGF-A
through transcriptional mechanisms [12] – was abolished (Fig. 1a,
upper and middle panels). Of note, H89 also prevented ATRA-induced
RARβ up-regulation (Fig. 1a, upper panel, inset), which reinforces the
view that MSK1 mediates the increase in RARβ expression induced by
PGE2. It might be argued that these results also point out to cAMP-
dependent protein kinase, an enzyme towhichH89 has a similar afﬁnity
than toMSK1 [29] and that it is activated by cAMP produced by adenyl-
ate cyclase once G-protein coupled EP2 and EP4 receptors have been ac-
tivated by PGE2 [30]. To address this issue it has to be taken into account
that activation of EGFR by PGE2 is also an EP receptor-dependent event
[17] and that it is critical for PGE2-induced RARβ/HIF-1α up-regulation
(so that it is fully prevented by the speciﬁc inhibitor of EGFR activation
AG1478) [17]. Therefore, if activation of cAMP-dependent protein ki-
nase is involved in PGE2-induced RARβ up-regulation, it should be an
event connected with the EGFR pathway. And because production of
cAMP is the immediate result of the activation of G-protein coupled
EP2/EP4 receptors, cAMP-depedent protein kinase should be upstream
of EGFR activation in the pathway leading to RARβ/HIF-1α up-
regulation upon treatment with PGE2. However, H89 did not prevent
the phosphorylation of EGFR upon treatment with PGE2 (Fig. 1a, lower
panel), which rules out that cAMP-dependent kinase is involved in
PGE2-induced EGFR. Besides, the view that the preventive effect of
H89 on PGE2-induced up-regulation of RARβ/HIF-1α is speciﬁcally
due to inhibition of MSK1 is further reinforced by the facts that DN-
MSK1 prevented the increase in RARβ/HIF-1α expression upon treat-
ment with PGE2 (Fig. 1a, middle panel) and that expression of RARβ
and HIF-1α was not increased by cAMP-increasing agent forskolin
(results are not shown).
Since the results in Fig. 1a suggested that PGE2 acts throughMSK1 to
increase RARβ expression, we next wanted to conﬁrm that MSK1 phos-
phorylation in HK-2 cells actually increased upon treatment with PGE2.
Western blot analysis indicated that phosphorylation of MSK1 rapidly
increased after treatment with PGE2 (Fig. 1b).
Transcriptionalmechanisms are involved in PGE2-induced RARβ up-
regulation [13]. Owing to the relevant role of H3 phosphorylation at
Ser10 in the activation of the RARβ gene promoter and taking account
that H3 Ser10 is aMSK1 target, we next askedwhether phosphorylation
of histone H3 Ser10 was also involved in PGE2-induced RARβ up-
regulation. To answer this questionweﬁrst studied thephosphorylation
of H3 Ser10 upon treatment with PGE2 in HK-2 cells which were
transfected or not with dn565 MSK1. Fig. 1c shows that treatment
with PGE2 resulted in increased phosphorylation of Ser10 in histone
H3, as assessed by immunoﬂuorescence and Western blot analysis,
which was prevented in dnMSK1-transfected cells or by pre-treating
cells with MSK1 inhibitor H89. We next investigated phosphorylation
of histone H3 on Ser10 occurring at the RARβ gene, using chromatin
immunoprecipitation assay after stimulation with PGE2. A semiquanti-
tative analysis of DNA input or immunoprecipitated DNA (with anti-
P-H3 Ser10), was carried out to detect a fragment of the RARβ gene
[24]. The results demonstrate that phosphorylation of histone H3 on
Ser10 at the RARβ gene increases in response to PGE2 (Fig. 1d). Finally,
in order to conﬁrm that MSK1 is actually required for PGE2-induced
gene transcription, we studied in PGE2-treated cells the effect of MSK1
inhibitor H89 on the activation of the RARE in the RARβ promoter and
on the expression of RARβ mRNA. We ﬁrst analyzed the effect of H89
on PGE2-induced RARE activity in HK-2 cells which were previously
transfected with tk-β-RARE-Luc (RARE construct from the RARβ
gene). We also repeated the experiment in PC3 cells and RWPE-1 cells
so as to ascertain that the effect of MSK1 inhibitor was not restricted
to HK2 cells. As shown in Fig. 1e, MSK1 inhibitor H89 prevented the in-
crease in RARE activity in all PGE2-treated cell lines.We then studied the
effect of H89 on the increase in RARβ mRNA induced by PGE2 in HK2
cells and found that it was prevented by the MSK1 inhibitor (Fig. 1e).
Quantitative RT-PCR, that the increase in both HIF-1alpha and VEGF ex-
pressions, is indeed due to up-regulated gene transcription.
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quired for PGE2-induced transcriptional up-regulation of RARβ and the
consequent increase in HIF-1α/VEGF-A expression.
MSK1 is activated downstream of the ERK or p38 MAPK pathway
in vivo [21] and both pathways, in turn, may be activated by EGFR
[18–20]. Since EGFR has to be obligatorily transactivated by PGE2 inFig. 1. PGE2 induces RARβ up-regulation through MSK1. a) PGE2-induced RARβ up-regulati
prevented by inhibition of MSK1. Upper panel: MSK1 inhibitor H89 prevents PGE2 and ATRA
H89 and then with 1 μM PGE2 or 10 μM ATRA (inset) for 45 min. The effect of these treatmen
induced increase in the expression of RARβ and HIF-1α is prevented by transfection with a MS
andmethods section and treated for 8 hwith PGE2.Middle panel (right):MSK1 inhibitor H89 pr
1 μMH89 and then with PGE2 for 48 h. VEGF-A production was quantiﬁed by ELISA. Middle pan
were treated for 4 or 8 h respectively with PGE2. Then total cell RNAwas extracted andmRNA le
prevented by H89. Cells were incubated ﬁrst for 1 h with 1 μMH89 and then with 1 μM PGE2 f
b) PGE2 increases MSK1 phosphorylation. HK-2 cells were incubated for up to 1 h with 1 μM P
ﬂuorescence analysis (right panel). c) PGE2 increases the phosphorilation of histone H3-Serine
tone H3-Serine 10 and HK-2 cells were incubated for up to 1 h with 1 μMPGE2 and phosphoryl
Inhibition of MSK1 prevents PGE2-induced histone-H3-Serine 10 phosphorylation and HK-2 cel
with 1 μMwith MSK1 inhibitor H89 (right) before being treated with PGE2 for 45 min. Then, h
Serine 10 phosphorylation was assessed by Western blot analysis. Equal H3 protein loading
Serine 10 at the RARβ promoter upon treatment with PGE2. HK-2 cells were treated up to 45
MSK-1 (Ser10) was performed. Input ampliﬁcation prior to IP was used (input DNA) as a load
of sequence along RARβ gene in PGE2-treated cells. e) PGE2 increases RARβ gene transcription. U
reporter construct. HK-2 (left panel) and PC3 and RWPE-1 cells (right panel) were transiently tr
incubated for 1 hwith H89 and incubatedwith orwithout 1 μMPGE2. Afterwards, luciferase acti
by Renilla luciferase activity and expressed as relative luminescence units (RLU). Lower panel: I
cellswere pre-treatedwith 1 μMH89 and then, incubated for 1 hwith PGE2. Then total cell RNA
were repeated three times. Bars are themean±S.D. of 3 different experiments. Statistical analys
protein loading was conﬁrmed by probing with an anti-β-actin antibody. For ChIP assay, a reporder to increase RARβ expression [17], we studied the role of ERK
and p38 MAPK in the mechanism through which EGFR mediates the
transcriptional up-regulation of RARβ induced by PGE2. To this end,
we ﬁrst studied whether pre-treatment with PD98059 (inhibitor of
the MAPK kinase which is upstream of ERK) or SB203580 (p38 MAPK
inhibitor) prevented the transcriptional up-regulation of RARβ leadingon, leading to transcriptional increase in HIF-1α expression and VEGF-A production, is
-induced increase in RARβ expression. HK-2 cells were incubated ﬁrst for 1 h with 1 μM
ts on RARβ expression was assessed by Western blot analysis. Middle panel (left): PGE2-
K1 dominant negative construct. HK-2 cells were transfected as described in the Materials
events PGE2-induced increase inVEGF-A production. Cellswere incubatedﬁrst for 1 hwith
el (insets): PGE2 increases the expression of HIF-1αmRNA and VEGF-AmRNA. HK-2 cells
velswere analyzed by Q-RT-PCR. Lower panel: PGE2-induced EGFR phosphorylation is not
or 5 min and expression of phosphorylated EGFR (EGFR-P) was assessed by Western blot.
GE2 and phosphorylation of MSK1 was assessed by Western blot (left panel) or immuno-
10 in a MSK1-dependent manner. Upper panel: PGE2 increases the phosphorilation of his-
ation of histone H3-serine 10 was assessed by immunoﬂuorescence analysis. Lower panel:
ls were transfectedwith aMSK-1 dominant negative construct (left) or pre-treated for 1 h
istones were isolated as described in the Materials and methods section and histone H3-
was conﬁrmed by probing with an anti-H3 antibody. d) Phosphorylation of histone H3-
min with PGE and chromatin immunoprecipitation assay using a speciﬁc antibody for p-
ing control. Semiquantitative PCR ampliﬁcation shows a signiﬁcant increase in the copies
pper panel: PGE2 increases the activity of a retinoic acid response element (RARE)-driven
ansfectedwith tk-β-RARE-Luc (RARE construct from the RARβ gene); then theywere pre-
vity in lysates of cells wasmeasured. Each bar represents the luciferase activity normalized
nhibitor of MSK1 activation H89 blocks the increase in RARβmRNA induced by PGE2. HK-2
was extracted and RARβmRNA levelswere analyzed by Q-RT-PCR. a) to e) All experiments
is: *P b 0.05 vs control. ForWestern blot analysis, a representative result is shownand equal
resentative semiquantitative PCR result is shown.
Fig. 1 (continued).
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sults (Fig. 2a) indicated that PGE2-induced increase in RARβ expression
and RARE activity, as well as HIF-1α up-regulation and increased pro-
duction of VEGF-Awere prevented by both inhibitors.We next assessed
by Western blot analysis the effect of PGE2 on the phosphorylation of
ERK and p38 MAPK and found that treatment with PGE2 determined a
quick and sustained increase in the phosphorylation of both enzymes
in HK-2 cells (Fig. 2b). As expected, PGE2 also induced phosphorylation
of EGFR (Fig. 2b, inset). In order to establish the dependence on EGFR ac-
tivity of the phosphorylation of ERK, p38 and MSK1 in PGE2-treated
cells, we studied the effect on these phosphorylations of pre-incubation with the inhibitor of the transactivation of EGFR AG1478
Our results indicated that the phosphorylation of ERK, p38 and MSK1
was prevented by AG1478 (Fig. 2c). Therefore, we next investigated
whether PGE2-induced phosphorylation of ERK and/or p38 MAPK was
an event upstream of the increase in the phosphorylation of MSK1
found upon treatment with PGE2 (Fig. 1). To this aim, HK-2 cells were
pre-treated with either PD98059 or SB203580 before being treated
with PGE2. Interestingly, PGE2-induced MSK1 phosphorylation was
prevented by both inhibitors (Fig. 2d), this fact indicates that activation
of ERK and p38 MAPK mediates the phosphorylation of MSK1 induced
by PGE2 (Fig. 2d, inset shows that PGE2-induced EGFR phosphorylation
2002 A.B. Fernández-Martínez, F.J. Lucio Cazaña / Biochimica et Biophysica Acta 1843 (2014) 1997–2004was not prevented by ERK1/2 or p38 inhibitors, which ruled out that
these kinases were upstream of EGFR activation). Taken together, the
results shown in Fig. 2 indicated that, following EGFR phosphorylation
upon treatment with PGE2, ERK1/2 and p38 MAPK are activated and
this event is crucial for PGE2-induced MSK1 activation.4. Discussion
We have previously found in proximal tubular HK2 cells that PGE2
up-regulates RARβwhen added exogenously to cells and also mediates
the increase in RARβ expression upon treatment with ATRA [12,13]. In
Fig. 3. Proposed EGFR/MAPK/MSK1 pathway through which PGE2 induces up-regulation
of RARβ.
2003A.B. Fernández-Martínez, F.J. Lucio Cazaña / Biochimica et Biophysica Acta 1843 (2014) 1997–2004both cases, increased RARβ expression resulted in up-regulation of
renoprotective factor HIF-1α [17] followed by increased production of
HIF-1α-regulated VEGF-A, which also has renoprotective effects. Fur-
ther studies indicated that EGFR is required for the transcriptional up-
regulation of RARβ by PGE2 [17] and here we provide data on the rele-
vant role of the EGFR-dependent activation of theMAPK/MSK1pathway
in the transcriptional up-regulation of RARβ induced by PGE2 (Fig. 3 de-
picts the proposed pathway). The role of MSK1 was conﬁrmed because
of i) there was no increase in RARβ protein expression (nor the conse-
quent enhancement in HIF-1α/VEGF-A expression) upon treatment
with PGE2 in HK-2 cells which were pre-treated with MSK1 inhibitor
H89 and/or transfected with dnMSK1, ii) PGE2 increased MSK1Fig. 2. Phosphorylation of ERK1/2 and p38 MAPK, downstream of PGE2-induced EGFR phosp
induced RARβ up-regulation, leading to HIF-1α up-regulation and increased production of VEG
treated for 1 h with 20 μM PD98059 (inhibitor of the MAPK kinase which, is upstream of ERK)
The effect of these treatments on the expression of RARβ and HIF-1αwas assessed by Wester
retinoic acid response element (RARE)-driven reporter construct. Each bar represents the lucif
cence units (RLU). Lower panel: Cells were treated as above and then, extracellular medium
p38 MAPK phosphorylation. HK-2 cells were incubated for up to 30 min with 1 μM PGE2 an
PGE2 increases EGFR phosphorylation. c) PGE2 increases the phosphorylation of ERK, p38 MA
AG1478, an inhibitor or EGFR activation, and thenwith 1 μMPGE2 for 30min. Afterwards, phosp
blot analysis. d) PGE2-induced increase in MSK1 phosphorylation is sensitive to inhibitors of E
SB203580 and then with 1 μM PGE2 for 30 min. Afterwards, phosphorylation of ERK, p38 MAP
ylation is not prevented by inhibitors of ERK or p38 MAPK. a) to d) All experiments were repe
*P b 0.05 vs control. For Western blot analysis, a representative result is shown and equal protphosphorylation and phosphorylation of the MSK1 target H3 Ser10 in
the RARβ gene promoter and iii) H89 and dnMSK1 prevented, respec-
tively, PGE2-induced RARE activation and PGE2-induced H3 Ser10 phos-
phorylation (both events being required for the transcription of the
RARβ gene [16,24]). Of note, H89 also inhibited in other cell lines the ac-
tivation of RARE by PGE2. Regarding the role of MAPKs, we found that
i) inhibitors of ERK1/2 or p38 (i.e. the MSK1 activators) prevented
PGE2-induced increase in RARE activity and RARβ protein expression
(and the consequent enhancement in HIF-1α/VEGF-A expression),
ii) phosphorylation of ERK1/2 and p38 increased upon treatment with
PGE2 and iii) PGE2-induced MSK1 phosphorylation was prevented by
inhibitors of EGFR, ERK1/2 or p38. However, while phosphorylation of
ERK1/2 and p38 was prevented by EGFR inhibitor AG1478, PGE2-
induced EGFR phosphorylation was not prevented by ERK1/2 or p38 in-
hibitors. These results indicated that activation of ERK1/2 and p38 upon
treatment with PGE2 is an event downstream of EGFR and that it leads
to MSK1 activation, RARβ up-regulation and the consequent increase
in the expression of renoprotective factors HIF-1α and VEGF-A (Fig. 3).
To our knowledge, there is only one previous report suggesting that
growth factor receptor-dependent MAPK signal pathways may induce
transcriptional activation of RARs [25]. This report describes the in-
volvement of growth factor-dependent Ras activity in the activation of
the RARβ promoter upon treatment of PC12 cells with nerve growth
factor, ﬁbroblast growth factor-2 or epidermal growth factor. Interest-
ingly, the receptors of EGF andﬁbroblast growth factor-2 have been pre-
viously shown to be activated by PGE2 [31–33]. Unfortunately, thework
of Cosgaya et al. did not analyze phosphorylation of EGFR or ERK1/2/p38
MAPK and MSK1, which are kinases downstream Ras [18–20].
Therefore, to the best of our knowledge, this is the ﬁrst time that an
EGFR-dependentMAPK signal pathway has been shown to induce tran-
scriptional activation of the RARβ gene.
We have not addressed the elucidation of the mechanism involved
in the activation of RARβ gene transcription by MAPK/MSK1 in PGE2-
treated cells, but the regulation by ATRA of RARα target genes – RARβ
being among them- [33] may give some insight into it. ATRA-activated
MSK1 has been found to be required for making RAREs in RARα target
genes accessible to RARα/RXR heterodimers through binding to
chromatin and phosphorylation of histone H3 (H3 S10), an event that
promotes other histone modiﬁcations and chromatin remodeling, ac-
cording to the histone code [21,23]. MSK1 is also required for DNA re-
cruitment of RARα [23], through RARα phosphorylation. Whether
MSK1 also controls the association/dissociation of coregulator com-
plexes it is still unclear but it has been shown that the upstream kinases
ERK1/2 and p38MAPK phosphorylate corepressors and coactivators of
RARs [14,34]. It is not unlikely that the mentioned mechanisms may
be involved in the activation of RARβ gene transcription by MAPK/
MSK1 in PGE2-treated cells given that the increase in PGE2 is critical
for the transcriptional up-regulation of RARβ by ATRA [13] and that
RARα contributes to the activation of the RARβ promoter by ATRA
[33]. Further studies should be done to conﬁrm this hypothesis.
HIF-1α is a keymodulator of cellular transcriptional response to low
oxygen conditions [35] and therefore it plays an important role in
kidney response to hypoxia [36]. Several stimuli which activate HIF
have shown renoprotective effects in ischemia-reperfusion, diabetichorylation, is crucial for MSK1 phosphorylation leading to RARβ up-regulation. a) PGE2-
F-A, is prevented by inhibitors of ERK and p38 MAPK. Upper panel: HK-2 cells were pre-
or 10 μM SB203580 (inhibitors of p38 MAPK) and then, incubated with PGE2 for 45 min.
n blot analysis. Inset: Effect of the inhibitors on PGE2-induced increase in the activity of a
erase activity normalized by Renilla luciferase activity and expressed as relative lumines-
was collected and VEGF production was measured by ELISA. b) PGE2 increases ERK and
d phosphorylation of ERK and p38 MAPK was assessed by Western blot analysis. Inset:
PK and MSK1 in an EGFR-dependent manner. Cells were pre-treated for 1 h with 1 μM
horylation of ERK, p38MAPK (left panel) andMSK1 (right panel)was assessed byWestern
RK and p38 MAPK. HK-2 cells were preincubated for 1 h with 20 μM PD98059 or 10 μM
K and MSK1 was assessed by Western blot analysis. Inset: PGE2-induced EGFR phosphor-
ated three times. Bars are the mean ± S.D. of 3 different experiments. Statistical analysis:
ein loading was conﬁrmed by probing with an anti-β-actin antibody.
2004 A.B. Fernández-Martínez, F.J. Lucio Cazaña / Biochimica et Biophysica Acta 1843 (2014) 1997–2004nephropathy, remnant kidneymodel, cisplatin nephropathy and chron-
ic anti-Thy1 nephritis (reviewed by Nangaku et al., 2008 [4]). VEGF-A
also has demonstrated protective effects in human renal proximal tubu-
lar cells [6], chronic renal disease [9,11] and experimental models of
renal disease [7,8,10]. Therefore, our results may contribute to new
therapeutic approaches based upon the pharmacological control of
HIF-1α/VEGF-A through the modulation of the PGE2/EGFR/MAPK/
MSK1/RARβ pathway.
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